# PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7

Study · id `cardio:ct-nct03222141` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03222141](<https://clinicaltrials.gov/study/NCT03222141>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03222141

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 583 participants.

## Technical summary

Registry record NCT03222141. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2015-09 (actual). Results posted on 2018-08-14.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 583 participants (enrolled count; ClinicalTrials.gov record NCT03222141, source copy `cardio:ctgov-nct03222141-2021-05-12`, retrieved 2026-10-26)
- Started: 2013-10 (actual) (ClinicalTrials.gov record NCT03222141, source copy `cardio:ctgov-nct03222141-2021-05-12`, retrieved 2026-10-26)
- Primary completion: 2015-09 (actual) (ClinicalTrials.gov record NCT03222141, source copy `cardio:ctgov-nct03222141-2021-05-12`, retrieved 2026-10-26)
- Completion: 2020-08 (actual) (ClinicalTrials.gov record NCT03222141, source copy `cardio:ctgov-nct03222141-2021-05-12`, retrieved 2026-10-26)
- Results first posted: 2018-08-14 (ClinicalTrials.gov record NCT03222141, source copy `cardio:ctgov-nct03222141-2021-05-12`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT03222141, source copy `cardio:ctgov-nct03222141-2021-05-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03222141-2021-05-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7
- Acronym: PII S3HR/NR7
- Condition: Symptomatic Severe Aortic Stenosis
- Intervention (Device): TAVR Implantation of the THV Prosthesis
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: a628780faf7f93c961d73d318c54e9f7e564903f4ba782708f368beb679fba66
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
